|
See related Certican tab information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Zuellig |
|
Contents |
Everolimus |
|
Indications |
In combination w/ ciclosporin (for microemulsion) & corticosteroids for the prophylaxis of organ rejection in adults at low to moderate immunological risk receiving an allogeneic renal or cardiac transplant.
Click to view Certican detailed prescribing infomation |
|
Dosage |
Adult Initially 0.75 mg bid administered as soon as possible after transplantation. Adjust dose at 4- to 5-day intervals based on achieved blood levels, tolerability, response, change in co-medications & clinical situation. Recommended everolimus whole blood trough levels: 3-8 ng/mL.
Click to view Certican detailed prescribing infomation |
|
Overdosage |
View Certican overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (Take consistently either always w/ or always w/o meals. Avoid grapefruit juice.). |
|
Contraindications |
[Click for Certican detailed prescribing infomation] |
|
Special Precautions |
Hepatic impairment. Monitor patients for skin neoplasms; minimise exposure to UV light & sunlight. Increased susceptibility to infections. Established hyperlipidaemia. Monitor renal function. Pregnancy & lactation.
Click to view Certican detailed prescribing infomation |
|
Adverse Drug Reactions |
Viral, bacterial & fungal infections, sepsis, leucopenia & other hematological disorders, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, HTN, lymphocele, venous thromboembolism, pneumonia, GI disturbances, acne, surgical wound complication, UTI, oedema, pain.
View ADR Monitoring Form |
|
Drug Interactions |
Antifungal agents, macrolides, Ca-channel blockers, rifampicin, cisapride, metoclopramide, bromocriptine, cimetidine, danazol, HIV-protease inhibitors, St John's wort, anticonvulsants, rifabutin, grapefruit juice, live vaccines.
View more drug interactions with Certican |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Caution For Usage |
For caution against possible variation of physical aspect of medicine... click to view Certican detailed prescribing infomation |
|
Storage |
View Certican storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Certican description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Certican mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Certican tablet |
|
Certican 0.25 mg x 6 x 10's |
 |
|
Certican 0.5 mg x 6 x 10's |
 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Zuellig
|
|
|
|
